Table 1.
Concentration of l-DOPA, dopamine and their metabolites in striatal astrocytes 4 h after methyl-l-DOPA (100 µM) and/or 3-OMD (10 µM) exposure
| Control | 3-OMD | Methyl-l-DOPA | 3-OMD + methyl-l-DOPA | |
|---|---|---|---|---|
| l-DOPA | N.D. | N.D. | 411.0 ± 12.1** | 347.0 ± 15.6**, ## |
| DA | N.D. | N.D. | N.D. | N.D. |
| DOPAC | N.D. | N.D. | N.D. | N.D. |
| HVA | N.D. | N.D. | N.D. | N.D. |
| 3-OMD | N.D. | 12.5 ± 1.02** | 15.3 ± 1.57** | 26.0 ± 0.83**, ## , $$ |
Striatal astrocytes were treated with methyl-l-DOPA (100 µM) and/or 3-OMD (10 µM) for 4 h. The concentrations of l-DOPA, DA, DOPAC, HVA and 3-OMD were measured by HPLC assay. N.D: not detected. Data (pmol/mg protein) are presented as mean ± SEM (n = 4)
* p < 0.05, ** p < 0.001 versus control group
## p < 0.001 versus methyl-l-DOPA-treated group
$$p < 0.001 versus 3-OMD-treated group